Lv64
2300 积分 2021-07-20 加入
The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
3小时前
已完结
Targeting Multiple KRAS Mutations with High-Affinity Macrocyclic Inhibitors: From Discovery to Preclinical Validation
1天前
已完结
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation
1天前
已完结
Rapid Optimization Enabled by Single-Molecule Tracking: Discovery of a Potent RUVBL1/2 Inhibitor to Evaluate the Targeting of MYC-Driven Cancers
7天前
已关闭
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation
7天前
已完结
Development of a Direct-to-Biology Platform to Discover Potent MNK Inhibitors
7天前
已完结
Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor
15天前
已完结
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration
15天前
已完结
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor
15天前
已完结
Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor
15天前
已完结
皖公网安备34019202002308
